Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06043843
Other study ID # 2020/3137
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 16, 2021
Est. completion date June 2026

Study information

Verified date September 2023
Source Sengkang General Hospital
Contact Baskar Rajamanickam
Phone 69304463
Email research@skh.com.sg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction Diabetes is a global emergency with detrimental clinical and financial consequences. Poorly managed diabetes leads to a myriad of serious complications, especially cardiovascular and infectious complications, with consequent increased cost and mortality rate. For Muslims in particular, the annual fasting month of Ramadan is one such period when diabetes control is essential. Adequate adjustments in diabetes management need to be made in line with the allowed mealtimes to avoid the risk of diabetes complications during Ramadan. Objective Investigators aim to investigate the effectiveness of Ramadan-focused structured diabetes tele-education to reduce diabetes complications during Ramadan fasting for Muslims with diabetes in South East Asia. Methodology In a parallel group randomized controlled trial, investigators aim to recruit 300 adults with diabetes who are able to fast at least 15 days in Ramadan. You will be randomized to the intervention group comprising of a Ramadan-focused structured diabetes tele-education and control group receiving standard care. You will be reviewed again after Ramadan. The primary outcome is the incidence of hypoglycemia in Ramadan. The secondary outcomes are incidence of other diabetes complications in Ramadan episodes including hyperglycemia, episodes of acute infections, attendances in clinic and emergency department, hospital admissions, and compliance to recommendations for diabetes management during Ramadan. Clinical Significance The study enables investigators to evaluate Ramadan-focused structured diabetes tele-education to reduce the risk of diabetes complications for a large population during the fasting month.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date June 2026
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years to 100 Years
Eligibility Inclusion Criteria: - Adults with diabetes planning to fast in Ramadan, 1. Adults with type 2 diabetes aged at least 21 years old, 2. Able to fast at least 15 days in Ramadan based on experience of fasting in previous year's Ramadan, 3. Underlying type 2 diabetes treated with basal insulin and one or more doses of prandial insulin, or at least twice-daily premixed insulin 4. Performed laboratory tests as per standard care - glycated haemoglobin (HbA1c), serum Low Density Lipoprotein- cholesterol, serum triglycerides, serum High Density Lipoprotein- cholesterol, serum Total cholesterol and serum creatinine 5. Ability to give informed consent, 6. Ability to perform self-monitoring blood glucose 7. Have had diabetes-related clinic visits or hospitalization in the past 10 months. 8. Have the capacity for video conferencing (internet connection with mobile phone or computer) Exclusion Criteria: 1. Severe diabetes complications including end-stage renal failure 2. Severe hypoglycemia and hyperglycemic crises within the last 3 months 3. Advanced comorbidities negating the ability to fast 4. Pregnancy 5. Patients on oral medications alone or oral medications plus basal insulin alone 6. Patients on sulfonylureas

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Focused diabetes tele-education and medication adjustment based on guidelines with remote monitoring from trial of fasting from before to throughout Ram
Ramadan-focused online education by physician, specialist nurse, and dietitian via video conferencing Fasting and exemptions Self-monitoring of blood glucose Acute diabetes complications and treatment Ramadan nutritional plan Safe physical activity You will be taught to record Meal plans Physical activities Blood glucose monitoring, and Monitoring for diabetes complications Perform a trial fasting day prior to Ramadan. Medication adjustments will be made according to the Diabetes and Ramadan Alliance guideline as well as individualized modifications based on their HbA1c as follows Baseline HbA1c Recommended dose reduction < 8% 30% 8 to 10% 15% > 10% None 2) Glucose monitoring up to 4 times daily Before Ramadan for 1 week During Ramadan After Ramadan for 1 week uploaded into an online portal for data collection, without remote monitoring.

Locations

Country Name City State
Singapore Sengkang General Hospital Singapore

Sponsors (9)

Lead Sponsor Collaborator
Sengkang General Hospital Changi General Hospital, Khoo Teck Puat Hospital, Singapore General Hospital, Universiti Kebangsaan Malaysia Medical Centre, Universiti Putra Malaysia, Universiti Sains Malaysia, Universiti Teknologi Mara, University of Malaya

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare first incidence rate of hypoglycaemia or severe hypoglycemia between intervention and control groups in Ramadan 4 weeks
Secondary Compare the first incidence rate of hypoglycemia or severe hypoglycemia between intervention and control groups in Ramadan when compared to 4 weeks before and 4 weeks post-Ramadan 12 weeks
Secondary Compare the first incidence rate of other complications in Ramadan - hyperglycemia and crises, acute infections, clinic and emergency department attendances and hospital admissions 12 weeks
Secondary Compare the compliance to current Ramadan treatment recommendations for diabetes based on number of blood glucose monitoring during Ramadan 4 weeks
Secondary Compare the compliance to current Ramadan treatment recommendations for diabetes based on number of days of fast terminated in the event of hypoglycaemia or hyperglycemia 12 weeks
Secondary Compare the weight changes after Ramadan as compared to pre-Ramadan weight 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A